Beta-thalassemia epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
 
(8 intermediate revisions by the same user not shown)
Line 3: Line 3:
{{CMG}};{{AE}}{{MHP}}
{{CMG}};{{AE}}{{MHP}}
==Overview==
==Overview==
The prevalence of beta-thalassemia carrier is 1.5% of the world population which is mainly in regions with a historical association with [[malaria]], including the Mediterranean, Middle East, Central Asia, Indian subcontinent, and parts of Southeast Asia and Africa. The incidence of beta-thalassemia is 42,000 per year. It affects both males and females in a similar demographic manner.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
Line 8: Line 9:
There are insufficient data about the exact prevalence of beta-thalassemia.
There are insufficient data about the exact prevalence of beta-thalassemia.
*The prevalence of beta-thalassemia carrier is 1.5% of the world population.<ref name="pmid28293406">{{cite journal| author=De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M et al.| title=β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. | journal=Mediterr J Hematol Infect Dis | year= 2017 | volume= 9 | issue= 1 | pages= e2017018 | pmid=28293406 | doi=10.4084/MJHID.2017.018 | pmc=5333734 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28293406  }} </ref>
*The prevalence of beta-thalassemia carrier is 1.5% of the world population.<ref name="pmid28293406">{{cite journal| author=De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M et al.| title=β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. | journal=Mediterr J Hematol Infect Dis | year= 2017 | volume= 9 | issue= 1 | pages= e2017018 | pmid=28293406 | doi=10.4084/MJHID.2017.018 | pmc=5333734 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28293406  }} </ref>
*More than 90% of the cases live in a geographic "belt" extending from the Mediterranean basin and parts of Africa, throughout the Middle East, the Indian subcontinent, Southeast Asia, and Melanesia in to the Pacific Islands (regions with historical association with malaria).<ref name="pmid23331260">{{cite journal |vauthors=Ladis V, Karagiorga-Lagana M, Tsatra I, Chouliaras G |title=Thirty-year experience in preventing haemoglobinopathies in Greece: achievements and potentials for optimisation |journal=Eur J Haematol |volume=90 |issue=4 |pages=313–22 |date=April 2013 |pmid=23331260 |doi=10.1111/ejh.12076 |url=}}</ref><ref name="pmid25058394">{{cite journal |vauthors=Kountouris P, Lederer CW, Fanis P, Feleki X, Old J, Kleanthous M |title=IthaGenes: an interactive database for haemoglobin variations and epidemiology |journal=PLoS One |volume=9 |issue=7 |pages=e103020 |date=2014 |pmid=25058394 |pmc=4109966 |doi=10.1371/journal.pone.0103020 |url=}}</ref>
*More than 90% of the cases live in a geographic "belt" extending from the Mediterranean basin and parts of Africa, throughout the Middle East, the Indian subcontinent, Southeast Asia, and Melanesia into the Pacific Islands (regions with a historical association with [[malaria]]).<ref name="pmid23331260">{{cite journal |vauthors=Ladis V, Karagiorga-Lagana M, Tsatra I, Chouliaras G |title=Thirty-year experience in preventing haemoglobinopathies in Greece: achievements and potentials for optimisation |journal=Eur J Haematol |volume=90 |issue=4 |pages=313–22 |date=April 2013 |pmid=23331260 |doi=10.1111/ejh.12076 |url=}}</ref><ref name="pmid25058394">{{cite journal |vauthors=Kountouris P, Lederer CW, Fanis P, Feleki X, Old J, Kleanthous M |title=IthaGenes: an interactive database for haemoglobin variations and epidemiology |journal=PLoS One |volume=9 |issue=7 |pages=e103020 |date=2014 |pmid=25058394 |pmc=4109966 |doi=10.1371/journal.pone.0103020 |url=}}</ref>
*There are increases in the number of cases through North America and Europe, which reflects the increased rates of migrations, refugees and adaptation of children.<ref name="pmid31233463">{{cite journal |vauthors=Barry RM, Chretien C, Kirby M, Gallant G, Leppington S, Robitaille N, Corriveau-Bourque C, Stoffman J, Wu J, Leaker M, Klaassen RJ |title=Syrian Refugees and Their Impact on Health Service Delivery in the Pediatric Hematology/Oncology Clinics Across Canada |journal=J Pediatr Hematol Oncol |volume=42 |issue=2 |pages=e107–e109 |date=March 2020 |pmid=31233463 |doi=10.1097/MPH.0000000000001524 |url=}}</ref>
*There are increases in the number of cases through North America and Europe, which reflects the increased rates of migrations, refugees and adaptation of children.<ref name="pmid31233463">{{cite journal |vauthors=Barry RM, Chretien C, Kirby M, Gallant G, Leppington S, Robitaille N, Corriveau-Bourque C, Stoffman J, Wu J, Leaker M, Klaassen RJ |title=Syrian Refugees and Their Impact on Health Service Delivery in the Pediatric Hematology/Oncology Clinics Across Canada |journal=J Pediatr Hematol Oncol |volume=42 |issue=2 |pages=e107–e109 |date=March 2020 |pmid=31233463 |doi=10.1097/MPH.0000000000001524 |url=}}</ref>
*Gender distribution: It affects both males and females in a similar demographic manner.
*Gender distribution: It affects both males and females in a similar demographic manner. Lahiry P, Al-Attar SA, Hegele RA. Understanding beta-thalassemia with a focus on the Indian subcontinent and the Middle East. The open hematology journal. 2008 Jan 22;2(1).


===Incident===
===Incident===
*The incidence of beta-thalassemia is 42,000 per year.<ref name="pmid27390837">{{cite journal| author=Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG et al.| title=β-Thalassemia and ocular implications: a systematic review. | journal=BMC Ophthalmol | year= 2016 | volume= 16 | issue=  | pages= 102 | pmid=27390837 | doi=10.1186/s12886-016-0285-2 | pmc=4938965 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27390837  }} </ref>
*The incidence of beta-thalassemia is 42,000 per year.<ref name="pmid27390837">{{cite journal| author=Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG et al.| title=β-Thalassemia and ocular implications: a systematic review. | journal=BMC Ophthalmol | year= 2016 | volume= 16 | issue=  | pages= 102 | pmid=27390837 | doi=10.1186/s12886-016-0285-2 | pmc=4938965 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27390837  }} </ref>
*Recent studies suggest that around 23000 infants with beta-thalassemia major are born every year and up to 90% of these infants are in low or middle-income countries.<ref name="pmid28293406">{{cite journal| author=De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M et al.| title=β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. | journal=Mediterr J Hematol Infect Dis | year= 2017 | volume= 9 | issue= 1 | pages= e2017018 | pmid=28293406 | doi=10.4084/MJHID.2017.018 | pmc=5333734 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28293406  }} </ref>
*Recent studies suggest that around 23000 infants with beta-thalassemia major are born every year and up to 90% of these infants are in low- or middle-income countries.<ref name="pmid28293406">{{cite journal| author=De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M et al.| title=β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint. | journal=Mediterr J Hematol Infect Dis | year= 2017 | volume= 9 | issue= 1 | pages= e2017018 | pmid=28293406 | doi=10.4084/MJHID.2017.018 | pmc=5333734 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28293406  }} </ref>


==References==
==References==

Latest revision as of 05:53, 25 August 2023

Beta-thalassemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Beta-thalassemia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Beta-thalassemia epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Beta-thalassemia epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Beta-thalassemia epidemiology and demographics

CDC on Beta-thalassemia epidemiology and demographics

Beta-thalassemia epidemiology and demographics in the news

Blogs on Beta-thalassemia epidemiology and demographics

Directions to Hospitals Treating Beta-thalassemia

Risk calculators and risk factors for Beta-thalassemia epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Maryam Hadipour, M.D.[2]

Overview

The prevalence of beta-thalassemia carrier is 1.5% of the world population which is mainly in regions with a historical association with malaria, including the Mediterranean, Middle East, Central Asia, Indian subcontinent, and parts of Southeast Asia and Africa. The incidence of beta-thalassemia is 42,000 per year. It affects both males and females in a similar demographic manner.

Epidemiology and Demographics

Prevalence

There are insufficient data about the exact prevalence of beta-thalassemia.

  • The prevalence of beta-thalassemia carrier is 1.5% of the world population.[1]
  • More than 90% of the cases live in a geographic "belt" extending from the Mediterranean basin and parts of Africa, throughout the Middle East, the Indian subcontinent, Southeast Asia, and Melanesia into the Pacific Islands (regions with a historical association with malaria).[2][3]
  • There are increases in the number of cases through North America and Europe, which reflects the increased rates of migrations, refugees and adaptation of children.[4]
  • Gender distribution: It affects both males and females in a similar demographic manner. Lahiry P, Al-Attar SA, Hegele RA. Understanding beta-thalassemia with a focus on the Indian subcontinent and the Middle East. The open hematology journal. 2008 Jan 22;2(1).

Incident

  • The incidence of beta-thalassemia is 42,000 per year.[5]
  • Recent studies suggest that around 23000 infants with beta-thalassemia major are born every year and up to 90% of these infants are in low- or middle-income countries.[1]

References

  1. 1.0 1.1 De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M; et al. (2017). "β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint". Mediterr J Hematol Infect Dis. 9 (1): e2017018. doi:10.4084/MJHID.2017.018. PMC 5333734. PMID 28293406.
  2. Ladis V, Karagiorga-Lagana M, Tsatra I, Chouliaras G (April 2013). "Thirty-year experience in preventing haemoglobinopathies in Greece: achievements and potentials for optimisation". Eur J Haematol. 90 (4): 313–22. doi:10.1111/ejh.12076. PMID 23331260.
  3. Kountouris P, Lederer CW, Fanis P, Feleki X, Old J, Kleanthous M (2014). "IthaGenes: an interactive database for haemoglobin variations and epidemiology". PLoS One. 9 (7): e103020. doi:10.1371/journal.pone.0103020. PMC 4109966. PMID 25058394.
  4. Barry RM, Chretien C, Kirby M, Gallant G, Leppington S, Robitaille N, Corriveau-Bourque C, Stoffman J, Wu J, Leaker M, Klaassen RJ (March 2020). "Syrian Refugees and Their Impact on Health Service Delivery in the Pediatric Hematology/Oncology Clinics Across Canada". J Pediatr Hematol Oncol. 42 (2): e107–e109. doi:10.1097/MPH.0000000000001524. PMID 31233463.
  5. Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG; et al. (2016). "β-Thalassemia and ocular implications: a systematic review". BMC Ophthalmol. 16: 102. doi:10.1186/s12886-016-0285-2. PMC 4938965. PMID 27390837.


Template:WikiDoc Sources